奥曲肽治疗晚期原发性肝癌的疗效观察  

Clinical study of octreotide for advanced hepatocellular carcinoma

作　　者：陈逸恒[1] 欧盛秋[1] 程伟民[1] 李春珊[1] 杨杨[1] 

机构地区：[1]广西中医学院第一附属医院肿瘤血液科,广西南宁530027

出　　处：《现代肿瘤医学》2010年第9期1793-1794,共2页Journal of Modern Oncology

基　　金：广西壮族自治区科学基金资助项目(编号:桂科青0542062)

摘　　要：目的:观察生长抑素类似物奥曲肽治疗晚期原发性肝癌的临床疗效。方法:收集40例晚期原发性肝癌患者,治疗组20例,使用奥曲肽0.2mg,皮下注射,每12小时1次,直至病情进展停药;对照组20例,仅接受积极的支持治疗,每1个月进行1次疗效评价,比较两组疗效。结果:治疗组中无CR,1例PR,4例MR,6例SD,9例PD。总有效率为25%;对照组中无CR、PR、MR,6例SD,14例PD,总有效率为0%,两组有显著性差异(P<0.05)。治疗组中位生存期为6.5个月,对照组中位生存期为2.5个月(P<0.05);治疗组TTP为3.5个月,对照组1.5个月(P<0.05);治疗组较对照组患者的AFP水平明显下降(P<0.05),生活质量有明显提高,上消化道出血的发生率降低(P<0.05)。结论:奥曲肽治疗晚期原发性肝癌能有效延长患者的生存期,提高生活质量。Objective：To evaluate the effect of octreotide for advanced hepatocellular carcinoma（HCC）. Methods： Twenty HCC patients were treated with octreotide at the dose of 0.2mg q12 h till the disease progresses, while twenty patients were given the best supportive care only. Results： There was significant difference in the response rate between two group （ P 〈 0.05 ）. Patients treated with oetreotide had an advantage in duration of survival time of 6.5 months vs 2.5 months, also an advantage in media aliment development time with 3.5 months vs 1.5 months in the control group and there was significant difference between the two groups （ P 〈 0.05 ）. Octreotide could improve the quality of life, decrease the upper gastrointestinal hemorrhage. Conclusion： Octreotide therapy can to improve the quality of life and have a survival benefit in advanced hepatoeellalar carcinoma patients.

关 键 词：生长抑素/奥曲肽 原发性肝癌 晚期 

分 类 号：R735.7[医药卫生—肿瘤]